1. Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/- mouse: magnetic resonance imaging assessment.
- Author
-
Olzinski AR, Turner GH, Bernard RE, Karr H, Cornejo CA, Aravindhan K, Hoang B, Ringenberg MA, Qin P, Goodman KB, Willette RN, Macphee CH, Jucker BM, Sehon CA, and Gough PJ
- Subjects
- Angiotensin II administration & dosage, Animals, Anti-Inflammatory Agents pharmacokinetics, Aortic Diseases immunology, Aortic Diseases pathology, Apolipoproteins E genetics, Atherosclerosis immunology, Atherosclerosis pathology, Contrast Media, Dextrans, Dietary Fats administration & dosage, Disease Models, Animal, Ferrosoferric Oxide, Humans, Immunohistochemistry, Infusion Pumps, Implantable, Macrophages immunology, Macrophages pathology, Magnetite Nanoparticles, Mice, Mice, Knockout, Mice, Transgenic, Naphthyridines pharmacokinetics, Peritonitis immunology, Peritonitis prevention & control, Receptors, CCR2 genetics, Receptors, CCR2 metabolism, Time Factors, Anti-Inflammatory Agents pharmacology, Aortic Diseases diet therapy, Apolipoproteins E deficiency, Atherosclerosis drug therapy, Macrophages drug effects, Magnetic Resonance Imaging, Naphthyridines pharmacology, Receptors, CCR2 antagonists & inhibitors
- Abstract
Unlabelled: Purpose- This study assessed the pharmacological effect of a novel selective C-C chemokine receptor (CCR) 2 antagonist (GSK1344386B) on monocyte/macrophage infiltration into atherosclerotic plaque using magnetic resonance imaging (MRI) in an atherosclerotic mouse model., Methods and Results: Apolipoprotein E(-/-) mice expressing human CCR2 were fed a Western diet (vehicle group) or a Western diet plus10 mg/kg per day of GSK1344386B (GSK1344386B group). After the baseline MRI, mice were implanted with osmotic pumps containing angiotensin II, 1000 ng/kg per minute, to accelerate lesion formation. After five weeks of angiotensin II administration, mice received ultrasmall superparamagnetic iron oxide, an MRI contrast agent for the assessment of monocyte/macrophage infiltration to the plaque, and underwent imaging. After imaging, mice were euthanized, and the heart and aorta were harvested for ex vivo MRI and histopathological examination. After 5 weeks of dietary dosing, there were no significant differences between groups in body or liver weight or plasma cholesterol concentrations. An in vivo MRI reflected a decrease in ultrasmall superparamagnetic iron oxide contrast agent uptake in the aortic arch of the GSK1344386B group (P<0.05). An ex vivo MRI of the aortic root also reflected decreased ultrasmall superparamagnetic iron oxide uptake in the GSK1344386B group and was verified by absolute iron analysis (P<0.05). Although there was no difference in aortic root lesion area between groups, there was a 30% reduction in macrophage area observed in the GSK1344386B group (P<0.05)., Conclusions: An MRI was used to noninvasively assess the decreased macrophage content in the atherosclerotic plaque after selective CCR2 inhibition.
- Published
- 2010
- Full Text
- View/download PDF